Baidu
map

2018 中国白血病异基因造血干细胞移植后复发的监测,治疗和预防共识(英文版)

2018-09-11 中华医学会血液学分会 Cancer Lett. 2018 Sep 11.

同种异体造血肝细胞移植(allo-HSCT)是白血病患者一项重要的治疗方法,然而,疾病复发仍是移植后患者死亡的主要原因。本文主要总结了白血病异基因造血干细胞移植后复发的监测,治疗和预防的相关内容并提出相应指导建议。

中文标题:

2018 中国白血病异基因造血干细胞移植后复发的监测,治疗和预防共识(英文版)

英文标题:

The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.

发布日期:

2018-09-11

简要介绍:

同种异体造血肝细胞移植(allo-HSCT)是白血病患者一项重要的治疗方法,然而,疾病复发仍是移植后患者死亡的主要原因。本文主要总结了白血病异基因造血干细胞移植后复发的监测,治疗和预防的相关内容并提出相应指导建议。 

拓展指南:白血病相关指南:

下载附件:

(因为版权问题,不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2213387, encodeId=9d3c221338e9e, content=好棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28389308098, createdName=ms2000001511174628, createdTime=Fri Jul 05 09:58:23 CST 2024, time=2024-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345748, encodeId=8281345e48d2, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/09/19/e1e884d57e871a7fec508a4a7d39a647.jpg, createdBy=f7952445895, createdName=123e4f94m24暂无昵称, createdTime=Wed Sep 19 23:13:02 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345738, encodeId=683f345e385f, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed Sep 19 22:11:35 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2024-07-05 ms2000001511174628

    好棒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2213387, encodeId=9d3c221338e9e, content=好棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28389308098, createdName=ms2000001511174628, createdTime=Fri Jul 05 09:58:23 CST 2024, time=2024-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345748, encodeId=8281345e48d2, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/09/19/e1e884d57e871a7fec508a4a7d39a647.jpg, createdBy=f7952445895, createdName=123e4f94m24暂无昵称, createdTime=Wed Sep 19 23:13:02 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345738, encodeId=683f345e385f, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed Sep 19 22:11:35 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2018-09-19 123e4f94m24暂无昵称

    很棒

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2213387, encodeId=9d3c221338e9e, content=好棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28389308098, createdName=ms2000001511174628, createdTime=Fri Jul 05 09:58:23 CST 2024, time=2024-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345748, encodeId=8281345e48d2, content=很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/09/19/e1e884d57e871a7fec508a4a7d39a647.jpg, createdBy=f7952445895, createdName=123e4f94m24暂无昵称, createdTime=Wed Sep 19 23:13:02 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345738, encodeId=683f345e385f, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed Sep 19 22:11:35 CST 2018, time=2018-09-19, status=1, ipAttribution=)]
    2018-09-19 明月清辉

    谢谢分享,学习了

    0

Baidu
map
Baidu
map
Baidu
map